Ucb
UCB, or UCB S.A., is a global biopharmaceutical company headquartered in Belgium. Founded in 1928, UCB has established itself as a leader in the biopharmaceutical industry, focusing on the development of innovative therapies for neurological and immunological disorders. With a strong presence in Europe and North America, UCB is dedicated to improving the lives of patients through its core products, including treatments for epilepsy, Parkinson's disease, and autoimmune conditions. The company is renowned for its commitment to research and development, which has led to significant milestones such as the launch of several groundbreaking therapies. UCB's unique approach combines advanced science with patient-centric solutions, positioning it as a key player in the global healthcare market. With a robust pipeline and a focus on unmet medical needs, UCB continues to make notable strides in the biopharmaceutical landscape.
DitchCarbon Score
How does Ucb's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ucb's score of 92 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ucb's reported carbon emissions
In 2024, UCB reported total carbon emissions of approximately 790,866,000 kg CO2e, with significant contributions from Scope 1, 2, and 3 emissions. Specifically, Scope 1 emissions were about 21,718,000 kg CO2e, while Scope 2 emissions totalled approximately 16,291,000 kg CO2e (location-based). The majority of emissions stemmed from Scope 3, amounting to around 769,143,000 kg CO2e, primarily from purchased goods and services (692,013,000 kg CO2e) and business travel (24,873,000 kg CO2e). UCB has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 GHG emissions by 73% by 2030 from a 2019 base year, and to achieve a 90% reduction by 2045. For Scope 3 emissions, the company targets a 48% reduction by 2030 and a 90% reduction by 2045. Additionally, UCB commits to ensuring that 80% of its suppliers by emissions will have science-based targets by 2028. These targets align with UCB's long-term goal of reaching net-zero greenhouse gas emissions across its value chain by 2045. The company’s commitments are consistent with the Science Based Targets initiative (SBTi) and reflect a strong commitment to sustainability within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 44,059,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 5,316,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 0,000 |
| Scope 3 | 568,003,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ucb is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
